Client News

STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes

Data to be presented at inaugural STORM Therapeutics RNA Epigenetics in Human Disease Conference in Cambridge, UK 18 September 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the … Continue reading “STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes”

By Optimum

Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis … Continue reading “Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH